Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 11 04:00PM ET
2.36
Dollar change
+0.24
Percentage change
11.32
%
Index- P/E- EPS (ttm)-0.23 Insider Own0.84% Shs Outstand145.26M Perf Week21.03%
Market Cap343.45M Forward P/E- EPS next Y-0.36 Insider Trans0.00% Shs Float144.30M Perf Month19.19%
Income-27.99M PEG- EPS next Q-0.14 Inst Own2.02% Short Float3.52% Perf Quarter-10.27%
Sales0.00M P/S- EPS this Y7.23% Inst Trans- Short Ratio44.45 Perf Half Y-7.81%
Book/sh0.87 P/B2.71 EPS next Y-58.52% ROA-24.05% Short Interest5.08M Perf Year14.01%
Cash/sh0.83 P/C2.83 EPS next 5Y- ROE-25.75% 52W Range1.66 - 3.34 Perf YTD-1.67%
Dividend Est.- P/FCF- EPS past 5Y9.98% ROI-21.96% 52W High-29.24% Beta2.22
Dividend TTM- Quick Ratio18.25 Sales past 5Y944.09% Gross Margin- 52W Low42.17% ATR (14)0.13
Dividend Ex-Date- Current Ratio18.25 EPS Y/Y TTM21.49% Oper. Margin- RSI (14)66.19 Volatility6.64% 6.01%
Employees- Debt/Eq0.01 Sales Y/Y TTM-100.00% Profit Margin- Recom1.43 Target Price7.57
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q17.69% Payout- Rel Volume4.03 Prev Close2.12
Sales Surprise-34.63% EPS Surprise3.11% Sales Q/Q- EarningsAug 29 AMC Avg Volume114.25K Price2.36
SMA2016.90% SMA5018.96% SMA2001.42% Trades Volume460,666 Change11.32%
Date Action Analyst Rating Change Price Target Change
May-17-24Initiated CapitalOne Overweight $10
Aug-03-23Initiated Robert W. Baird Outperform $7
Aug-03-21Initiated Ladenburg Thalmann Buy $8.30
Jul-16-21Resumed Maxim Group Buy $8
Sep-28-18Initiated B. Riley FBR Buy $7.75
Feb-15-18Reiterated Maxim Group Buy $7 → $5
Dec-10-24 08:00AM
Nov-14-24 08:15AM
08:00AM
Oct-29-24 08:00AM
Oct-28-24 08:00AM
08:00AM Loading…
Oct-17-24 08:00AM
Oct-10-24 08:00AM
Oct-04-24 06:12AM
Oct-03-24 08:00AM
Sep-24-24 08:00AM
Sep-18-24 08:00AM
Sep-16-24 08:00AM
Aug-20-24 08:00AM
Aug-14-24 08:00AM
Aug-07-24 08:00AM
08:00AM Loading…
Jul-31-24 08:00AM
Jul-22-24 08:00AM
Jul-17-24 08:00AM
Jul-15-24 08:39AM
Jul-12-24 09:15AM
07:41AM
Jul-11-24 06:40PM
Jul-03-24 08:00AM
Jun-27-24 07:34AM
Jun-25-24 08:00AM
Jun-05-24 06:00AM
Jun-02-24 08:38PM
May-15-24 08:00AM
May-02-24 08:00AM
Apr-29-24 08:00AM
08:00AM Loading…
Apr-24-24 08:00AM
Apr-18-24 08:00AM
Apr-17-24 08:00AM
Mar-24-24 07:55AM
Mar-05-24 08:00AM
Feb-05-24 03:11AM
Jan-30-24 08:00AM
Jan-04-24 08:00AM
Dec-21-23 08:00AM
Dec-07-23 08:00AM
Nov-22-23 08:00AM
Nov-09-23 08:00AM
Nov-06-23 08:00AM
Nov-03-23 12:00PM
Nov-02-23 08:00AM
Oct-31-23 08:00AM
Oct-25-23 08:00AM
Oct-24-23 08:00AM
Oct-23-23 08:00AM
Oct-16-23 08:00AM
Oct-03-23 08:00AM
Sep-21-23 08:00AM
Sep-05-23 09:00AM
Aug-03-23 10:03AM
Aug-01-23 08:00AM
Jul-31-23 08:00AM
08:00AM
Jul-28-23 08:00AM
Jul-06-23 05:57PM
Jun-27-23 08:00AM
08:00AM
Jun-20-23 08:00AM
Jun-14-23 07:01PM
Jun-09-23 05:21PM
Jun-07-23 08:00AM
Jun-05-23 08:00AM
Jun-02-23 08:00AM
May-29-23 08:00AM
May-26-23 08:00AM
May-25-23 08:00AM
May-24-23 08:00AM
May-17-23 08:00AM
May-16-23 08:00AM
May-09-23 08:00AM
May-02-23 08:00AM
May-01-23 08:00AM
Apr-27-23 08:00AM
Apr-26-23 10:00AM
08:00AM
Apr-17-23 09:00AM
Apr-12-23 07:55PM
Mar-31-23 08:00AM
Mar-30-23 08:00AM
Mar-23-23 08:00AM
Mar-14-23 08:00AM
Feb-06-23 08:00AM
Jan-30-23 08:00AM
Jan-04-23 08:00AM
Dec-23-22 08:00AM
Dec-08-22 08:00AM
Dec-06-22 08:00AM
Dec-02-22 08:00AM
Nov-29-22 08:00AM
Nov-16-22 03:14PM
Nov-14-22 08:00AM
Nov-10-22 11:10AM
09:00AM
Nov-09-22 08:00AM
Nov-04-22 08:00AM
Nov-02-22 08:00AM
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK'781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.